Mutants of pneumolysin that are non-toxic by reason of amino acid
substitutions have been constructed. These mutants elicit an immune
response in animals that is reactive to wild-type pneumolysin. The
invention also encompasses vaccines for humans based on these mutants,
including vaccines comprising conjugates with pneumococcal capsular
polysaccharides.
